These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21628141)

  • 41. Diabetes: syringes and pens.
    Godfrey K
    Community Nurse; 1998 Sep; 4(8):25-6. PubMed ID: 9814172
    [No Abstract]   [Full Text] [Related]  

  • 42. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe.
    Lee LJ; Li Q; Reynolds MW; Pawaskar MD; Corrigan SM
    J Med Econ; 2011; 14(1):75-86. PubMed ID: 21231863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Making life easier for insulin users: one step forward with incremental advances in insulin delivery systems.
    Lock JP
    J Diabetes Sci Technol; 2011 Sep; 5(5):1200-2. PubMed ID: 22027318
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
    Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents.
    Kadiri A; Chraibi A; Marouan F; Ababou MR; el Guermai N; Wadjinny A; Kerfati A; Douiri M; Bensouda JD; Belkhadir J; Arvanitis Y
    Diabetes Res Clin Pract; 1998 Jul; 41(1):15-23. PubMed ID: 9768368
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Which insulin, regimen and device in type 2 diabetes?
    Drug Ther Bull; 2010 Dec; 48(12):134-8. PubMed ID: 21123289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preference for insulin delivery systems among current insulin users and nonusers.
    Summers KH; Szeinbach SL; Lenox SM
    Clin Ther; 2004 Sep; 26(9):1498-505. PubMed ID: 15531012
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
    von Ferber L; Köster I; Hauner H
    Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump.
    Keith K; Nicholson D; Rogers D
    Clin Pediatr (Phila); 2004; 43(1):69-74. PubMed ID: 14968895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions.
    Johnson JL; Downes JM; Obi CK; Asante NB
    J Diabetes Sci Technol; 2017 May; 11(3):618-622. PubMed ID: 27898390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of insulin delivery systems.
    Siddiqui NI; Rahman S; Nessa A
    Mymensingh Med J; 2008 Jan; 17(1):102-10. PubMed ID: 18285745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach.
    Davey P; Grainger D; MacMillan J; Rajan N; Aristides M; Dobson M
    Pharmacoeconomics; 1998 Mar; 13(3):347-58. PubMed ID: 10178660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The business of intensive insulin therapy for type 2 diabetes patients: where it all began for me.
    Norton E
    J Diabetes Sci Technol; 2009 Nov; 3(6):1521-3. PubMed ID: 20144409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature.
    Salas M; Hughes D; Zuluaga A; Vardeva K; Lebmeier M
    Value Health; 2009 Sep; 12(6):915-22. PubMed ID: 19402848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Adherence and Outcomes Benefits of Using a Connected, Reusable Auto-Injector for Self-Injecting Biologics: A Narrative Review.
    Antalfy A; Berman K; Everitt C; Alten R; Latymer M; Godfrey CM
    Adv Ther; 2023 Nov; 40(11):4758-4776. PubMed ID: 37733212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of factors affecting the accuracy of low-dose insulin dosage using syringes and vials: a cross-sectional study in a Japanese regional hospital.
    Kondo M; Saji R; Yamada Y; Hayashi M; Shirai T
    Diabetol Int; 2024 Jul; 15(3):544-549. PubMed ID: 39101185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Performance of a new reusable insulin pen.
    Penfornis A
    Diabetes Technol Ther; 2011 Mar; 13(3):373-9. PubMed ID: 21291331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of insulin pen use in the United States and the United Kingdom.
    Da Costa S; Brackenridge B; Hicks D
    Diabetes Educ; 2002; 28(1):52-6, 59-60. PubMed ID: 11852744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.